NASDAQ:RGNX

REGENXBIO Stock Forecast, Price & News

$28.76

-0.56 (-1.91 %)

(As of 10/30/2020 12:00 AM ET)

Add

Compare

Today's Range

$28.16

Now: $28.76▼

$29.58

50-Day Range

$26.52

MA: $28.33▼

$29.95

52-Week Range

$20.03

Now: $28.76▼

$54.97

Volume235,401 shs

Average Volume421,807 shs

Market Capitalization$1.07 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.95

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
REGENXBIO has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.00, REGENXBIO has a forecasted upside of 129.5% from its current price of $28.76.
Amount of Analyst Coverage
REGENXBIO has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
REGENXBIO has received 381 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
REGENXBIO has received 331 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
REGENXBIO has received 53.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote “Outperform” if you believe RGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
REGENXBIO does not currently pay a dividend.
Dividend Growth
REGENXBIO does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, REGENXBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.10% of the stock of REGENXBIO is held by insiders.
Percentage Held by Institutions
77.45% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for REGENXBIO are expected to grow in the coming year, from ($2.97) to ($2.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of REGENXBIO is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of REGENXBIO is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
REGENXBIO has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.55 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RGNX

Previous Symbol

CUSIPN/A

CIK1590877

Webwww.regenxbio.com

Phone240-552-8181

Employees257

Debt

Debt-to-Equity RatioN/A

Current Ratio8.19

Quick Ratio8.19

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$35.23 million

Price / Sales30.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value$12.23 per share

Price / Book2.35

Profitability

EPS (Most Recent Fiscal Year)($3.26)

Net Income$-94,730,000.00

Net Margins-222.24%

Return on Equity-31.06%

Return on Assets-28.08%

Miscellaneous

Outstanding Shares37,334,000

Market Cap$1.07 billion

Next Earnings Date11/4/2020 (Confirmed)

OptionableOptionable

$28.76

-0.56 (-1.91 %)

(As of 10/30/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

How has REGENXBIO's stock been impacted by Coronavirus?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RGNX stock has decreased by 12.6% and is now trading at $28.76.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of REGENXBIO?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for REGENXBIO.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for REGENXBIO.

How can I listen to REGENXBIO's earnings call?

REGENXBIO will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.02. The biotechnology company earned $16.60 million during the quarter, compared to the consensus estimate of $22.23 million. REGENXBIO had a negative net margin of 222.24% and a negative return on equity of 31.06%. The firm's quarterly revenue was up 110.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.04) earnings per share.
View REGENXBIO's earnings history.

What price target have analysts set for RGNX?

7 equities research analysts have issued 12-month price targets for REGENXBIO's shares. Their forecasts range from $42.00 to $95.00. On average, they anticipate REGENXBIO's share price to reach $66.00 in the next year. This suggests a possible upside of 129.5% from the stock's current price.
View analysts' price targets for REGENXBIO.

Who are some of REGENXBIO's key competitors?

Some companies that are related to REGENXBIO include Kodiak Sciences (KOD), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), Immunovant (IMVT), Ablynx (ABLYF), bluebird bio (BLUE), Twist Bioscience (TWST), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), Editas Medicine (EDIT), Vaxcyte (PCVX), Sorrento Therapeutics (SRNE) and Forma Therapeutics (FMTX).
View all competitors.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), Crispr Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:

Mr. Kenneth T. Mills, CEO, Pres & Director (Age 45, Pay $986.83k)
Mr. Vittal K. Vasista, Chief Financial Officer (Age 52, Pay $636.48k)
Mr. Patrick J. Christmas II, Chief Legal Officer (Age 49, Pay $610.82k)
Dr. Olivier Danos, Chief Scientific Officer (Age 62, Pay $622.73k)
Dr. Stephen Pakola, Chief Medical Officer (Age 51, Pay $549.77k)

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional shareholders include DekaBank Deutsche Girozentrale (0.20%), BNP Paribas Arbitrage SA (0.10%), Comerica Bank (0.08%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.04%) and Exane Derivatives (0.01%). Company insiders that own REGENXBIO stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista.
View institutional ownership trends for REGENXBIO.

Which institutional investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Comerica Bank, and State of Alaska Department of Revenue. Company insiders that have sold REGENXBIO company stock in the last year include Curran Simpson, Donald J Hayden Jr, and Vittal Vasista.
View insider buying and selling activity for REGENXBIO.

Which institutional investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Louisiana State Employees Retirement System, Pacer Advisors Inc., Nisa Investment Advisors LLC, Exane Derivatives, and Exane Derivatives.
View insider buying and selling activity for REGENXBIO.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $28.76.

How big of a company is REGENXBIO?

REGENXBIO has a market capitalization of $1.07 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. REGENXBIO employs 257 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings